The complaint was filed on April 22nd, 2015 in the US District Court for the Northern District of Illinois under docket case number 1:14-cv-01748.
In this specific case, the plaintiff reports that her husband began using AndroGel (produced by AbbVie) in January of 2012. In April of 2013 the plaintiff’s husband suffered an acute heart attack, which the plaintiff claims was caused by her husband’s exposure to AndroGel.
As a result, the plaintiff seeks to obtain compensatory and non-compensatory damages from AbbVie alleging that the company acted negligently by designing a defective drug, failing to warn the public about its dangers and misrepresenting the drug’s safety.
The complaint is one of more than 2,000 which have now been consolidated in a Multidistrict Litigation (MDL) for testosterone therapy products.
About AndroGel & The Pending Products Liability Litigation
Testosterone Replacement Therapy (TRT) supplements have become increasingly popular in America over the last decade and AndroGel has been one of the leading brands.
AndroGel was FDA-approved for the treatment of Hypogonadism and Hypogonadotropic Hypogonadism, however doctors frequently prescribed the drug to men who had not been diagnosed with either of these conditions.
Additionally, several medical studies have now associated the use of testosterone replacement drugs with adverse side effects including heart attack and stroke.
As a result, legal action is now being taken by men who have taken “Low T” medications and have suffered from adverse events that may have been linked to their use of testosterone replacement supplements.
An MDL was formed in the US District Court for the Eastern District of Illinois which has consolidated more than 2,000 lawsuits relating to the alleged dangers of testosterone therapy products.
These lawsuits are being filed against several drug companies involved in the production, marketing and distribution of Low T products including AbbVie Inc., Auxilium and Endo Pharmacueticals among others.
“The first bellwether trials for the testosterone MDL are scheduled to begin in October 2016,” reported Laurence Banville, Esq. of Banville Law.
“In the meantime, we are assisting all individuals wishing to file a lawsuit or seeking legal guidance,” said Banville.
Please direct all questions about this press release and the pending litigation to Laurence Banville, Esq. at 888-478-9711.